CTLA4 and nonpapillary renal cell carcinoma: The absence of therapeutic responses suggested that the VpR ccRCC model might represent a good system to study the mechanisms underlying intrinsic or acquired anti-PD-1 plus anti-CTLA-4 checkpoint therapy resistance that is a frequent feature of human ccRCC.